Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Mar;64(3):1026–1029. doi: 10.1128/iai.64.3.1026-1029.1996

Platelet-activating-factor-mediated pathogenesis in Lyme disease.

E Isogai 1, K Kimura 1, N Fujii 1, T Nishikawa 1, N Ishii 1, D Postic 1, G Baranton 1, H Isogai 1
PMCID: PMC173874  PMID: 8641753

Abstract

This study describes a role of platelet-activating factor (PAF) as a potential inducer of inflammation in infection with Borrelia burgdorferi. Two approaches were taken. The first involved the use of a PAF antagonist to show the lack of an inflammatory response in skin lesions. The second was to show that the PAF antagonist reduced platelet aggregation when the spirochetes were incubated with polymorphonuclear leukocytes.

Full Text

The Full Text of this article is available as a PDF (175.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambrosio G., Oriente A., Napoli C., Palumbo G., Chiariello P., Marone G., Condorelli M., Chiariello M., Triggiani M. Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. J Clin Invest. 1994 Jun;93(6):2408–2416. doi: 10.1172/JCI117248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baranton G., Postic D., Saint Girons I., Boerlin P., Piffaretti J. C., Assous M., Grimont P. A. Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis. Int J Syst Bacteriol. 1992 Jul;42(3):378–383. doi: 10.1099/00207713-42-3-378. [DOI] [PubMed] [Google Scholar]
  3. Barbour A. G. Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med. 1984 Jul-Aug;57(4):521–525. [PMC free article] [PubMed] [Google Scholar]
  4. Beck G., Benach J. L., Habicht G. S. Isolation of interleukin 1 from joint fluids of patients with Lyme disease. J Rheumatol. 1989 Jun;16(6):800–806. [PubMed] [Google Scholar]
  5. Benach J. L., Fleit H. B., Habicht G. S., Coleman J. L., Bosler E. M., Lane B. P. Interactions of phagocytes with the Lyme disease spirochete: role of the Fc receptor. J Infect Dis. 1984 Oct;150(4):497–507. doi: 10.1093/infdis/150.4.497. [DOI] [PubMed] [Google Scholar]
  6. Berger B. W., Clemmensen O. J., Ackerman A. B. Lyme disease is a spirochetosis. A review of the disease and evidence for its cause. Am J Dermatopathol. 1983 Apr;5(2):111–124. [PubMed] [Google Scholar]
  7. Braquet P., Touqui L., Shen T. Y., Vargaftig B. B. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987 Jun;39(2):97–145. [PubMed] [Google Scholar]
  8. Burgdorfer W., Barbour A. G., Hayes S. F., Benach J. L., Grunwaldt E., Davis J. P. Lyme disease-a tick-borne spirochetosis? Science. 1982 Jun 18;216(4552):1317–1319. doi: 10.1126/science.7043737. [DOI] [PubMed] [Google Scholar]
  9. Burgdorfer W. The New Zealand white rabbit: an experimental host for infecting ticks with Lyme disease spirochetes. Yale J Biol Med. 1984 Jul-Aug;57(4):609–612. [PMC free article] [PubMed] [Google Scholar]
  10. Coburn J., Barthold S. W., Leong J. M. Diverse Lyme disease spirochetes bind integrin alpha IIb beta 3 on human platelets. Infect Immun. 1994 Dec;62(12):5559–5567. doi: 10.1128/iai.62.12.5559-5567.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Coburn J., Leong J. M., Erban J. K. Integrin alpha IIb beta 3 mediates binding of the Lyme disease agent Borrelia burgdorferi to human platelets. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7059–7063. doi: 10.1073/pnas.90.15.7059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Comstock L. E., Thomas D. D. Penetration of endothelial cell monolayers by Borrelia burgdorferi. Infect Immun. 1989 May;57(5):1626–1628. doi: 10.1128/iai.57.5.1626-1628.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Defosse D. L., Johnson R. C. In vitro and in vivo induction of tumor necrosis factor alpha by Borrelia burgdorferi. Infect Immun. 1992 Mar;60(3):1109–1113. doi: 10.1128/iai.60.3.1109-1113.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Galbe J. L., Guy E., Zapatero J. M., Peerschke E. I., Benach J. L. Vascular clearance of Borrelia burgdorferi in rats. Microb Pathog. 1993 Mar;14(3):187–201. doi: 10.1006/mpat.1993.1019. [DOI] [PubMed] [Google Scholar]
  15. Georgilis K., Steere A. C., Klempner M. S. Infectivity of Borrelia burgdorferi correlates with resistance to elimination by phagocytic cells. J Infect Dis. 1991 Jan;163(1):150–155. doi: 10.1093/infdis/163.1.150. [DOI] [PubMed] [Google Scholar]
  16. Hanahan D. J. Platelet activating factor: a biologically active phosphoglyceride. Annu Rev Biochem. 1986;55:483–509. doi: 10.1146/annurev.bi.55.070186.002411. [DOI] [PubMed] [Google Scholar]
  17. Isogai E., Tanaka S., Braga I. S., 3rd, Itakura C., Isogai H., Kimura K., Fujii N. Experimental Borrelia garinii infection of Japanese quail. Infect Immun. 1994 Aug;62(8):3580–3582. doi: 10.1128/iai.62.8.3580-3582.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kornblatt A. N., Steere A. C., Brownstein D. G. Infection in rabbits with the Lyme disease spirochete. Yale J Biol Med. 1984 Jul-Aug;57(4):613–616. [PMC free article] [PubMed] [Google Scholar]
  19. Lynch J. M., Henson P. M. The intracellular retention of newly synthesized platelet-activating factor. J Immunol. 1986 Oct 15;137(8):2653–2661. [PubMed] [Google Scholar]
  20. Ma Y., Weis J. J. Borrelia burgdorferi outer surface lipoproteins OspA and OspB possess B-cell mitogenic and cytokine-stimulatory properties. Infect Immun. 1993 Sep;61(9):3843–3853. doi: 10.1128/iai.61.9.3843-3853.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Oda M., Satouchi K., Yasunaga K., Saito K. Polymorphonuclear leukocyte-platelet interactions: acetylglyceryl ether phosphocholine-induced platelet activation under stimulation with chemotactic peptide. J Biochem. 1986 Nov;100(5):1117–1123. doi: 10.1093/oxfordjournals.jbchem.a121815. [DOI] [PubMed] [Google Scholar]
  22. Peterson P. K., Clawson C. C., Lee D. A., Garlich D. J., Quie P. G., Johnson R. C. Human phagocyte interactions with the Lyme disease spirochete. Infect Immun. 1984 Nov;46(2):608–611. doi: 10.1128/iai.46.2.608-611.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Prescott S. M., Zimmerman G. A., McIntyre T. M. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proc Natl Acad Sci U S A. 1984 Jun;81(11):3534–3538. doi: 10.1073/pnas.81.11.3534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rola-Pleszczynski M. Priming of human monocytes with PAF augments their production of tumor necrosis factor. J Lipid Mediat. 1990;2 (Suppl):S77–S82. [PubMed] [Google Scholar]
  25. Schmidli J., Hunziker T., Moesli P., Schaad U. B. Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis. J Infect Dis. 1988 Oct;158(4):905–906. doi: 10.1093/infdis/158.4.905. [DOI] [PubMed] [Google Scholar]
  26. Shoberg R. J., Thomas D. D. Specific adherence of Borrelia burgdorferi extracellular vesicles to human endothelial cells in culture. Infect Immun. 1993 Sep;61(9):3892–3900. doi: 10.1128/iai.61.9.3892-3900.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Snydman D. R., Schenkein D. P., Berardi V. P., Lastavica C. C., Pariser K. M. Borrelia burgdorferi in joint fluid in chronic Lyme arthritis. Ann Intern Med. 1986 Jun;104(6):798–800. doi: 10.7326/0003-4819-104-6-798. [DOI] [PubMed] [Google Scholar]
  28. Stafforini D. M., McIntyre T. M., Carter M. E., Prescott S. M. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem. 1987 Mar 25;262(9):4215–4222. [PubMed] [Google Scholar]
  29. Tanaka M. Induction of tissue factor-like activity of human monoblastic leukemia cell line by tumor necrosis factor-alpha. Thromb Res. 1989 Oct 15;56(2):201–211. doi: 10.1016/0049-3848(89)90162-x. [DOI] [PubMed] [Google Scholar]
  30. Terashita Z., Tsushima S., Yoshioka Y., Nomura H., Inada Y., Nishikawa K. CV-3988 - a specific antagonist of platelet activating factor (PAF). Life Sci. 1983 Apr 25;32(17):1975–1982. doi: 10.1016/0024-3205(83)90049-8. [DOI] [PubMed] [Google Scholar]
  31. Wallace J. L., Whittle B. J. Picomole doses of platelet-activating factor predispose the gastric mucosa to damage by topical irritants. Prostaglandins. 1986 May;31(5):989–998. doi: 10.1016/0090-6980(86)90028-6. [DOI] [PubMed] [Google Scholar]
  32. Wardlow M. L., Cox C. P., Meng K. E., Greene D. E., Farr R. S. Substrate specificity and partial characterization of the PAF-acylhydrolase in human serum that rapidly inactivates platelet-activating factor. J Immunol. 1986 May 1;136(9):3441–3446. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES